Kanvas Biosciences has secured an undisclosed investment from the Gates Foundation to develop its first synthetic microbiome replacement product targeting maternal environmental enteric dysfunction (EED). This funding will support the development of a treatment aimed at preventing maternal undernutrition and low infant birthweight. The company's focus is on leveraging global metagenomic data to create these novel therapeutic solutions.
